Food and Drug Administration (FDA) announced that it is restricting the unlawful entry of xylazine active pharmaceutical ingredients and finished dosage form drug products into the United States to address growing concerns of the chemical appearing in drugs such as illicitly manufactured fentanyl, methamphetamine, and cocaine. The agency warns that individuals who inject products containing xylazine can experience life-threatening symptoms, such as depressed breathing, blood pressure, heart rate, and body temperature. Individuals may also develop severe skin wounds and patches of dead and rotting tissue that can easily become infected and, if left untreated, may lead to amputation. Shipments of xylazine will undergo heightened FDA scrutiny to ensure that the imports of the drugs containing xylazine into the US are intended for legitimate veterinary supply. Veterinarians use xylazine to sedate large animals, such as horses and deer. More information is available on FDA’s website under news releases.